Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Business

ImmunoGen, Inc. Announces Webcast of Presentations at Multiple Investor Conferences in September


Print article Print article
© Business Wire 2010
2010-09-02 18:14:27 -

ImmunoGen, Inc : . (Nasdaq: IMGN), a biotechnology company that develops antibody-based targeted anticancer products, today announced that Company management will present at multiple investor conferences this month. The live webcast of each presentation can be accessed through the “Investor Information” section of the Company’s website, www.immunogen.com : ; a replay of each presentation will be available for one week.



- 2010 Morgan Stanley Global Healthcare Unplugged Conference8:00 a.m. EDT on September 13, 2010 in New York, NYPresenter.
Daniel Junius, President and CEO



- Stifel Nicolaus 2010 Healthcare Conference11:30 a.m. EDT on September 15, 2010 in Boston, MAPresenter: Gregory Perry, Senior Vice President and CFO
- Bank of America Merrill Lynch Global Healthcare Conference 20101:00 p.m. BST

(8:00 a.m. EDT) on September 16, 2010 in London, EnglandPresenter.
Daniel Junius, President and CEO

- UBS Global Life Sciences Conference12:00 p.m. EDT on September 20, 2010 in New York, NYPresenter: Gregory Perry, Senior Vice President and CFO

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies and the creation and attachment of potent cancer cell-killing agents. The Company’s Targeted Antibody Payload (TAP) technology uses engineered antibodies to deliver one of ImmunoGen’s proprietary cancer-cell killing agents specifically to tumor targets. Product candidates are in development through the Company’s own product programs and through ImmunoGen’s collaborations with Amgen, Bayer Schering Pharma, Biogen Idec, Biotest, Genentech (a member of the Roche Group), and sanofi-aventis. The most advanced compound using ImmunoGen’s TAP technology, T-DM1, is in Phase III testing through the Company’s collaboration with Genentech.



For Investors:ImmunoGen, Inc.Carol Hausner,

781-895-0600Executive Director, Investor Relations and Corporate
Communications info@immunogen.com : mailto:info@immunogen.com orFor

Media:Yates Public RelationsKathryn Morris, 914-204-6412


Author:
Hossam Abdel-Kader
e-mail
Web: www.pr-inside.com/
Phone: +43 1 9582319

Disclaimer: (c) 2012 Business Wire. All of the news releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com | BidVertiser